CS logo
small CS logo
University of Maryland School of Medicine - Center for Vaccine Development - Baltimore

Baltimore, Maryland, United States
State university system in Baltimore, Maryland
655 W Baltimore St S, Baltimore, MD 21201

About University of Maryland School of Medicine - Center for Vaccine Development - Baltimore


The University of Maryland School of Medicine, located in Baltimore City, Maryland, U.S., is the medical school of the University of Maryland, Baltimore and is affiliated with the University of Maryland Medical Center and Medical System.
  • Top Sponsors
  • Top Collaborators
  • Trials By Phase
  • Recruitment Status
  • Top Conditions
  • Intervention Types
  • Top Intervention Names
  • Trials By Gender
Lead Sponsor
# Trials
National Institute of Allergy and Infectious Diseases (NIAID)
35
University of Maryland, Baltimore
15
Sanaria Inc.
2
Intralytix, Inc.
1
LigoCyte Pharmaceuticals, Inc.
1
Novartis Vaccines
1
PATH
1
Pfizer
1
U.S. Army Medical Research and Development Command
1
Total Rows: 9

Clinical Trials at University of Maryland School of Medicine - Center for Vaccine Development - Baltimore


During the past decade, University of Maryland School of Medicine - Center for Vaccine Development - Baltimore conducted 28 clinical trials. In the 10-year time frame, 28 clinical trials started and 13 clinical trials were completed, i.e. on average, 46.4% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 11 clinical trials were completed. i.e. 73.3% of trials that started reached the finish line.
Created with Highcharts 11.1.0TrialsTrials Trend - Last 10 Years223311552288224411000011001133442222Started TrialsCompleted Trails2015201620172018201920202021202220230246810
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Elderly Influenza Vaccine Immunogenicity Substudy
2005-04-25
2005-05-30
Completed
60
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants
2007-03-01
2009-11-01
Completed
4,545
H5N1 (Clade 2) Vaccination of Adults and Elderly
2008-11-01
2009-11-01
Completed
517
Malaria Challenge With NF54 Strain
2009-03-01
2011-11-01
Completed
37
Phase 1 Norwalk Vaccine Study
2008-11-01
2009-10-01
Completed
61
Longitudinal Study of the Human Intestinal Microbiome
2009-07-23
2011-01-11
Completed
60
Safety and Efficacy Challenge Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella: Phase IIb
2010-01-01
2010-02-01
Terminated
20
Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection: Phase IIa
2010-01-01
2010-02-01
Terminated
20

Rows per page:

1–58 of 58

Clinical Trials Sponsors and Collaborators


Out of the total clinical trials conducted in "University of Maryland School of Medicine - Center for Vaccine Development - Baltimore" #1 sponsor was "National Institute of Allergy and Infectious Diseases (NIAID)" with 35 trials, followed by "University of Maryland, Baltimore" with 15 trials sponsored, "Sanaria Inc." with 2 trials sponsored, "Intralytix, Inc." with 1 trials sponsored and "LigoCyte Pharmaceuticals, Inc." with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "University of Maryland School of Medicine - Center for Vaccine Development - Baltimore" #1 collaborator was "PATH" with 3 trials as a collaborator, "Food and Drug Administration (FDA)" with 2 trials as a collaborator, "Medical Technology Enterprise Consortium (MTEC)" with 2 trials as a collaborator, "University of Maryland, Baltimore" with 2 trials as a collaborator and "Walter Reed Army Institute of Research (WRAIR)" with 2 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.
Created with Highcharts 11.1.0Top Leading SponsorsNational Institute ofAllergy and InfectiousDiseases (NIAID): 35National Institute ofAllergy and InfectiousDiseases (NIAID): 35University of Maryland,Baltimore: 15University of Maryland,Baltimore: 15Sanaria Inc.: 2Sanaria Inc.: 2Intralytix, Inc.: 1Intralytix, Inc.: 1LigoCytePharmaceuticals, Inc.: 1LigoCytePharmaceuticals, Inc.: 1Novartis Vaccines: 1Novartis Vaccines: 1PATH: 1PATH: 1Pfizer: 1Pfizer: 1U.S. Army MedicalResearch andDevelopmentCommand: 1U.S. Army MedicalResearch andDevelopmentCommand: 1

Created with Highcharts 11.1.0Top CollaboratorsPATH: 3PATH: 3Food and DrugAdministration (FDA): 2Food and DrugAdministration (FDA): 2Medical TechnologyEnterprise Consortium(MTEC): 2Medical TechnologyEnterprise Consortium(MTEC): 2University of Maryland,Baltimore: 2University of Maryland,Baltimore: 2Walter Reed ArmyInstitute of Research(WRAIR): 2Walter Reed ArmyInstitute of Research(WRAIR): 2GlaxoSmithKline: 1GlaxoSmithKline: 1Joint Warfighter MedicalResearch Program: 1Joint Warfighter MedicalResearch Program: 1National Institute ofAllergy and InfectiousDiseases (NIAID): 1National Institute ofAllergy and InfectiousDiseases (NIAID): 1Naval Medical ResearchCenter: 1Naval Medical ResearchCenter: 1PepTcell Limited (t/a SEEK): 1PepTcell Limited (t/a SEEK): 1

Clinical Trials Conditions at University of Maryland School of Medicine - Center for Vaccine Development - Baltimore


According to Clinical.Site data, the most researched conditions in "University of Maryland School of Medicine - Center for Vaccine Development - Baltimore" are "Influenza" (12 trials), "COVID-19" (4 trials), "Malaria" (4 trials), "Plasmodium Falciparum Infection" (4 trials) and "Shigella" (4 trials). Many other conditions were trialed in "University of Maryland School of Medicine - Center for Vaccine Development - Baltimore" in a lesser frequency.

Clinical Trials Intervention Types at University of Maryland School of Medicine - Center for Vaccine Development - Baltimore


Most popular intervention types in "University of Maryland School of Medicine - Center for Vaccine Development - Baltimore" are "Biological" (45 trials), "Drug" (21 trials), "Other" (20 trials) and "Device" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (15 trials), "AS03" (4 trials), "Remdesivir" (4 trials), "Phosphate Buffered Saline (PBS) diluent" (3 trials) and "Baricitinib" (2 trials). Other intervention names were less common.

Clinical Trials Genders at University of Maryland School of Medicine - Center for Vaccine Development - Baltimore


The vast majority of trials in "University of Maryland School of Medicine - Center for Vaccine Development - Baltimore" are 57 trials for "All" genders and 1 trials for "Female" genders.

Clinical Trials Status at University of Maryland School of Medicine - Center for Vaccine Development - Baltimore


Currently, there are NaN active trials in "University of Maryland School of Medicine - Center for Vaccine Development - Baltimore". undefined are not yet recruiting, 7 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 46 completed trials in University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, undefined suspended trials, and 3 terminated clinical trials to date.
Out of the total trials that were conducted in University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, 29 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 0 trials that are defined as “Not Applicable".
Created with Highcharts 11.1.0Trials By PhasePhase 1: 29Phase 1: 29Phase 2: 17Phase 2: 17Phase 3: 6Phase 3: 6Phase 4: 6Phase 4: 6Early Phase 1: 1Early Phase 1: 1

Created with Highcharts 11.1.0Trials StatusCompleted: 46Completed: 46Recruiting: 7Recruiting: 7Terminated: 3Terminated: 3Active, not recruiting: 2Active, not recruiting: 2